logo
Share SHARE
FONT-SIZE Plus   Neg

Strides Arcolab Gets US FDA Nod For Vancomycin Oral Capsules

Strides Arcolab Ltd. said it had received approval from the US FDA to market its generic Vancomycin Hydrochloride capsules in the strength of 125mg and 250 mg.

Vancomycin capsules is glycopeptides antibiotic used in the prophylaxis and treatment of infections caused by Gram-positive bacteria. It has traditionally been reserved as a drug of last resort, used only after treatment with other antibiotics had failed.

The company plans to launch the product immediately through US-based Alvogen on a profit-sharing basis, the company said.

As per IMS health data, Vancomycin capsules had total US sales of $332 million for the twelve months ended February 12, with no prior generic approvals.

Commenting on the development, Strides Group CEO Arun Kumar said, "Oral Vancomycin development is one among the many value generics programmes being undertaken at the Strides Group with a special focus to develop niche and difficult-to-manufacture products.''

At the BSE, Strides Arcolab closed Wednesday's trading at Rs 631.90, after touching a 52-week high of Rs.649 in the early trading session.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

More Breaking News

0 Articles
Editors Pick
Embark Veterinary Inc., a startup that makes dog DNA-testing kits for pet owners, vets and breeders, said it has raised $4.5 million in funding from investors and relocated its headquarters to Boston. The company intends to use the new funding to expand its canine genetic testing suite for pet owners, breeders, and veterinarians. Intel Corp. has completely shut down its wearables division about two weeks ago, CNBC reported, citing a person familiar with the matter. The company reportedly intends to focus on augmented reality. According to the CNBC report, Intel laid off about 80 percent of the team that made the Basis fitness watch in November 2016 and has now eliminated the division entirely. The Federal Trade Commission is investigating allegations that Amazon.com Inc. misled consumers about its pricing discounts, Reuters reported, citing a source close to the probe. The FTC probe is reportedly part of the agency's review of Amazon's proposed $13.4 billion deal to buy grocery chain Whole Foods Market Inc.
comments powered by Disqus
Follow RTT